Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments

Company Developments - Accuray Incorporated (ARAY) has entered into an agreement with TrueNorth Medical Physics LLC to enhance the capabilities of radiation oncology departments, providing supplementary services to hospitals [1][2] - TrueNorth will support the commissioning, physics, and dosimetry of Accuray's TomoTherapy, Radixact, and CyberKnife platforms, offering customized services tailored to hospital needs [2] - Accuray has been actively forming partnerships, including a collaboration with Oncopole Claudius Regaud and Airbus SAS to develop an AI-driven solution for predicting radiotherapy system performance [3] Industry Prospects - The global radiation therapy market, valued at $7.3 billion in 2022, is projected to grow at a rate of 8%, reaching over $14.9 billion by 2032, driven by increased efficiency and market demand [4] Notable Developments - In June, Accuray received approval from the Chinese National Medical Products Administration for its Precision Treatment Planning System, enhancing treatment accuracy and expanding access to care for cancer patients in China [5] - New data presented at the 2024 Radiosurgery Society Meeting supports the use of the CyberKnife System for treating high-risk and recurrent prostate cancer [5] Price Performance - Over the past six months, ARAY's shares have decreased by 34.5%, contrasting with a 5.8% increase in the industry and a 15.2% rise in the S&P 500 [6]